News | May 18, 2025
Hikal posts Q4 FY25 consolidated PAT at Rs. 50 Cr
In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 crore and EBIT growth of 65% to Rs 55 croe, on QoQ basis
In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 crore and EBIT growth of 65% to Rs 55 croe, on QoQ basis
Indraprastha Medical Corporation has reported total income of Rs. 340.10 crores during the period ended March 31, 2025
The company has posted net profit of Rs. 485.62 crores for the Financial Year ended March 31, 2025
The company has posted net profit of Rs. 1,414.44 crores for the Financial Year ended March 31, 2025
The company has posted net profit of Rs. 30.53 crores for the Financial Year ended March 31, 2025
The company has posted net profit of Rs. 0.54 crores for the Financial Year ended March 31, 2025
The company has posted net profit of Rs. 260.10 crores for the Financial Year ended March 31, 2025
IOL Chemicals and Pharmaceuticals has posted net profit of Rs.101.07 crores for the Financial Year ended March 31, 2025
Jubilant Pharmova has posted net profit of Rs. 839.4 crores for the Financial Year ended March 31, 2025
Net Profit increased by 15% to Rs. 146 crores in Q4 FY25 and 19% to Rs. 660 crores in FY25
Subscribe To Our Newsletter & Stay Updated
